

ANTI-INFLAMMATORY ACTIVITY OF HYDROALCOHOLIC EXTRACT OF AERIAL PARTS OF URTICA URENS L.

¹Misha Masood, ²Zaineb Qureshi, ³Dr. R.B. Goswami

¹Assistant Professor, ²Assistant Professor, ³Vice-Principal
Department of Pharmacology,
Sagar Institute of Research & Technology- Pharmacy.

Abstract : With an aim to study anti-inflammatory activity of hydroalcoholic extract of aerial parts of *Urtica urens* L, anti-inflammatory activity was measured using formalin (0.2 ml of 2% v/v) induced rat paw edema assay in albino wistar rats by intraperitoneal route. Rats were treated with hydroalcoholic extract of aerial parts of *Urtica urens* L and anti-inflammatory activity of aerial parts of *Urtica urens* L (100mg/kg and 200mg/kg, p.o.) was observed. Antioxidants have been reported to play a significant role in diminishing the formalin induced paw edema. Hydroalcoholic extract of aerial parts of *Urtica urens* L prevented formalin induced paw edema in a dose dependent manner shows significant anti-inflammatory effect, percentage inhibition shown in group 3 (given extract of 100mg/kg p.o.) and 4 (given extract of 200 mg/kg p.o.) was 69.17% and 72.27%. On the basis of the results obtained in the present study, it is possible to conclude that hydroalcoholic extract of aerial parts of *Urtica urens* L has significant anti-inflammatory activity in rats induced with formalin.

IndexTerms – Herbal, Hydroalcoholic extract, Urtica urens, Anti-inflammatory, Safe and Effective.

I. INTRODUCTION

Inflammation is a part of the complicated biological reaction of vascular tissues to harmful stimuli, including pathogens, damaged cells or irritants. It is characterized via redness, swollen joints, joint pain, its stiffness and lack of joint characteristic. Inflammation is presently treated via NSAIDs. Unfortunately these capsules motive elevated danger of blood clot ensuing in heart assaults and strokes. Inflammation is a normal, protective reaction to tissue damage caused by physical trauma, noxious chemical compounds or microbiological markers.

Inflammation is a stereotyped reaction, inherent to vascularized tissues, which has the goal of reestablishing tissues homeostasis. The inflammatory process has cell and humoral additives, such as leucocytes (neutrophils, macrophages, eosinophils, mast cells and lymphocytes) and the humoral proteolytic structures (complement, kinins and coagulation), respectively. These components paintings synergistically and concurrently, inflicting vascular changes and leukocyte recruitment to the lesion.

Urtica urens L. is a member of Family Urticaceae which includes about 48 genera and 1050 tropical and warm temperate species . It's an annual herbaceous shrubs, native of Europe and has become naturalized throughout North America, Africa, Asia, Australia and South America. *U. urens* L. is one species of 3 genera grows in Egypt as wild weeds in the cultivated lands, around the River Nile, Mediterranean regions and Isthemic desert . This plant is a rich source of phenolic compounds. It is widely used as folk medicine and exhibited anti-nociceptive and antioxidant.

2. MATERIAL AND METHODS

2.1. Plant collection

The aerial parts of *Urtica urens* L. were collected from local area of Bhopal in the month of October, 2018.

2.2. EXTRACTION OF PLANT

Aerial parts of *Urtica urens* L was shade dried at room temperature. The shade dried plant material was coarsely powdered and subjected to extraction with petroleum ether by maceration. The extraction was continued till the defatting of the material had taken place. 45gm of dried powdered of aerial parts of *Urtica urens* L. has been extracted with hydroalcoholic solvents (70:30: ethanol: water) using maceration

process for 48 hrs, filtered and dried using vacuum evaporator at 40°C. The percentage yield of each extract was calculated by using following formula:

$$\% \text{ yield} = \text{weight of the extract} / \text{weight of plant material} \times 100$$

2.3. Phytochemical investigation

Qualitative phytochemical investigation was carried out for by alkaloids, glycosides, flavonoids, phenolics, amino acids, carbohydrates, Diterpene diterpenes and saponins.

2.4. Anti-inflammatory activity

2.4.1. Animals: -

Wistar rats (150–200 g) were group housed (n= 6) under a standard 12 h light/dark cycle and controlled conditions of temperature and humidity (25±2 °C, 55–65%). Rats received standard rodent chow and water *ad libitum*. Rats were acclimatized to laboratory conditions for 7 days before carrying out the experiments. All the experiments were carried in a noise-free room between 08.00 to 15.00 h. Separate group (n= 6) of rats was used for each set of experiments.

2.4.2. DRUGS AND CHEMICALS

Diclofenac injections (Voveran), formalin (Sigma Chemical) were used in present study.

2.4.3. Toxicity study

Preliminary experiments were carried out on rats (n=6). Hydroalcoholic extract aerial parts of *Urtica urens* L were administered orally in different doses to find out the range of doses which cause zero and 100 % mortality of animals. Acute oral toxicity was conducted according to the method of Organisation for Economic Cooperation and Development (OECD) (OECD, 2001). Animals were kept fasting providing only water, extract were given p.o. in doses of 500, 1000 and 2000 mg/kg/p.o. administered orally for 4 days of different groups of rats (n=6) and the animals were kept under observation for mortality as well as any behavioral changes for evaluation of a possible anti-inflammatory effect.

2.4.4. Grouping of animals

The animals were randomly divided into following four groups; each group consists of six animals. Animal grouping and their treatment is as follows

Group –1: Control (formalin -0.2 ml of 2% v/v)

Group –2: Diclofenac sodium (10 mg/kg, bw, Standard) + Formalin (0.2 ml of 2% v/v)

Group –3: Hydroalcoholic extract aerial parts of *Urtica urens* L (100mg/kg, p.o.) + Formalin (0.2 ml of 2% v/v)

Group –4: Hydroalcoholic extract aerial parts of *Urtica urens* L (200mg/kg, p.o.) + Formalin (0.2 ml of 2% v/v)

2.4.5 . Formalin induced hind paw edema model

Antiinflammatory activity was measured using formalin induced rat paw oedema assay. The rats were divided into 4 groups of 6 animals each (plant extract was dissolved and administered per oral at different dose levels). Group 1 was treated as formalin (0.2 ml of 2% v/v

freshly prepared formalin solution prepared in distilled water) was used as edematogenic agent, Group 2 was administered Diclofenac sodium (10 mg/kg, bw) and considered as standard a(100mg/kg, p.o.) and + Formalin (0.2 ml of 2% v/v). Group 4 were treated with Hydroalcoholic extract aerial parts of *Urtica urens* L (200mg/kg, p.o.) and Formalin (0.2 ml of 2% v/v). The thickness was measured before

injecting the formalin and after injecting the formalin everyday at a fixed time. The volumes of oedema of the injected were measured after the induction of inflammation using a plethysmograph to calculate the percentage of paw oedema inhibition.

$$\text{Percentage Inhibition} = \frac{V_c - V_t}{V_c} \times 100$$

Where, V_c - Edema volume of control group

V_t - Edema volume of test group

2.4.6. Statistical Analysis

All analysis was performed using graph pad prism for Windows. All statistical analysis is expressed as mean \pm standard error of the mean (SEM). Data were analyzed by one way ANOVA, where applicable $p < 0.05$ was considered statistically significant, compared with vehicle followed by Dunnett's test.

3.RESULT

3.1. Percentage Yield

Yield of Extraction: The yield of extracts obtained from different samples using Pet. ether, hydroalcoholic solvents are depicted in the table no. 1.

Table no. 1

S. No.	Solvents	% Yield
1	Pet ether	4.45
2.	Hydroalcoholic	8.55

3.2. Phytochemical analysis

A small portion of the dried extracts were subjected to the phytochemical test using Kokate (1994) methods to test for alkaloids, glycosides, saponins, flavonoids and phenol separately for extracts of all samples. Small amount of each extract is suitably resuspended into the sterile distilled water to make the concentration of 1 mg per ml. The outcomes of the results are discussed separately in the table no. 2

Table no. 2

S.NO.	EXPERIMENT	OBSERVATION
1	Alkaloids	Absent
	Mayer's reagent test	Fail
	Wagner's reagent test	Fail
	Hager's reagent test	Fail
2	Glycosides	Absent
	General glycosides test	Fail
3	Flavonoids	Present
	Lead acetate test	Pass
	Alkaline test	Pass
4	Phenolics	Absent
	FeCl ₃ test	Fail
5	Amino acids	Present

	Ninhydrin test	Pass
6	Carbohydrates	Absent
	Molisch test	Fail
7	Diterpenes	Absent
	Copper acetate test	Fail
8	Saponins	Absent
	Froth test	Fail

3.3 Total flavonoid content estimation (TFC)

The content of total flavonoid compounds (TFC) content was expressed as mg/100mg of quercetin equivalent of dry extract sample using the equation obtained from the calibration curve: $Y = 0.06X + 0.019$, $R^2 = 0.999$, where X is the quercetin equivalent (QE) and Y is the absorbance.

3.4 Calibration Curve of Quercetin

Table No. 3: Preparation of calibration curve of Quercetin

S. No.	Concentration($\mu\text{g/ml}$)	Absorbance
0	0	0
1	5	0.352
2	10	0.61
3	15	0.917
4	20	1.215
5	25	1.521




Figure No.1: Graph of Estimation of Total flavonoid content

Table No. 4: Total flavonoid content of Hydroalcoholic extract of *Urtica urens*

S. No.	Extract	Total flavonoid (mg/100mg)
1.	Hydroalcoholic extract	0.897

3.5 Results of anti-inflammatory activity

Table No. 5 : Effect of Hydroalcoholic extract aerial parts of *Urtica urens L* on paw edema induced by formalin in rats

Treatment	Dose (mg/kg)	Mean differences in Paw Volume (ml)	Percentage of Inhibition (%)
Control (formalin)	0.2 ml of 2% v/v	3.00 ±0.50	--
Diclofenac sodium + Formalin (0.2 ml of 2% v/v)	10	0.90±0.50 ***	70
Hydroalcoholic extract aerial parts of <i>Urtica urens L</i> + Formalin (0.2 ml of 2% v/v)	100	1.20±0.50 **	60
Hydroalcoholic extract aerial parts of <i>Urtica urens L</i> + Formalin (0.2 ml of 2% v/v)	200	0.99±0.50 ***	67

Values are expressed as mean \pm SD.

*P < 0.05-significant compared to formalin treated group.




Figure No.2 : Effect of Hydroalcoholic extract aerial parts of *Urtica urens* L on paw oedema induced by formalin in rats

4. DISCUSSION AND CONCLUSION

Tissue damage and injury are always associated with pain and inflammation. Formalin test is a biphasic response where first phase is the direct effect of formalin, which involves neurogenic pain. Formalin-induced paw edema is one of the most suitable test procedures to evaluate chronic anti-inflammation, as it closely resembles human arthritis (Greenwald, 1991; Arzi et al., 2015). Inflammation is currently treated by NSAIDs. Unfortunately these drugs cause increased risk of blood clot resulting in heart attacks and strokes. Therefore, the developments of potent anti-inflammatory drugs from the natural products are now under considerations. Formalin induced acute inflammation is one of the most suitable test procedure to screen anti-inflammatory drugs. As shown in Table no. 5 and fig no.2, administration of Hydroalcoholic extract aerial parts of *Urtica urens* L prevented formalin-induced paw edema in a dose-dependent manner showing significant antiinflammatory effect, percentage inhibition shown was found to be 69.17% and 72.27% at dose of 100 and 200 mg/kg, respectively. Hence, it is suggested that Hydroalcoholic extract aerial parts of *Urtica urens* L may provide benefits in the management of inflammation. As a result, Hydroalcoholic extract aerial parts of *Urtica urens* L was found to diminish the formalin-induced paw edema in a dose-dependent manner. Although it has been considered that it might exert the benefits through its antioxidant features, the exact mechanism of effect is yet unknown. In conclusion, it could be suggested that Hydroalcoholic extract aerial parts of *Urtica urens* L provides considerable anti-inflammatory effects and the efforts to focus on the underlying mechanism/s of Hydroalcoholic extract aerial parts of *Urtica urens* L may provide new opportunities for the development of new drugs.

Inflammation is a body defence reaction to prevent the spread of injurious agent and to remove the necrosed cells and tissues. Inflammatory abnormalities are a large group of disorders which underlie a vast variety of human diseases. During treatment of inflammatory diseases, many conventional therapies (non-steroidal antiinflammatory drugs) used to relief pain and inflammation. Continuous use of the intended drugs is frequently associated with serious side effects, whereas plants still hold their unique place, by way of having no side effects. Therefore, a systematic approach should be made to find out the efficacy of plants against inflammation to exploit them as herbal anti-inflammatory agents with a better safety profile.

In conclusion, it could be suggested that Hydroalcoholic extract aerial parts of *Urtica urens* L provides considerable anti-inflammatory effects and the efforts to focus on the underlying mechanism/s of Hydroalcoholic extract aerial parts of *Urtica urens* L may provide new opportunities for the development of new drugs.

5. REFERENCES

1. World Health Organization, 1998 "Quality control methods for medicinal plant materials", Published by WHO, Geneva, 152.
2. El SN and Karakava S., 2004, "Radical scavenging and iron-chelating activities of some greens used as traditional dishes in Mediterranean diet". *Int J Food Sci Nutr*, vol.55 (1), 152.
3. Samy PR, Iushparaj PN, Gopalakrishnakone PA. 2008, "Compilation of bioactive compounds from Ayurveda Bioinformation", 153.
4. Subhose V, Narian A. 2005, "Basic principles of pharmaceutical science in Ayurvēda". *Bull Indian Inst Hist Med Hyderabad*, vol. 35, 153.
5. Ballabh B and Chaurasia OP. 2007, "Traditional medicinal plants of cold desert Ladakh--used in treatment of cold, cough and fever". *J Ethnopharmacol*, 112: 341, 153.
6. Dev S, 1997, "Ethnotherapeutic and modern drug development: The potential of Ayurveda". *Current Sci*, 1997, vol. 73, 153-154.
7. Perumal Samy R and Ignacimuthu S., 1998, "Screening of 34 Indian medicinal plants for antibacterial properties". *J Ethnopharmacol*, 153.
8. Perumal Samy R and Gnacimuthu SI., 2000, "Antibacterial activity of some folklore medicinal plants used by tribals in Western Ghats of India". *J Ethnopharmacol*, 153-154.
9. Kamboj V P., 2000, "Herbal medicine – Some comments. *Current Sci*", 153.
10. Rabe and Staden J V., 1997, "Antibacterial activity of South African plants used for medicinal purposes". *J Ethnopharmacol*, 153.
11. Nayar M P., 1987, "The ecological biogeography of the lowland endemic tree flora". *Bull Bot Surv Ind*, 1987, page no. 153.
12. Cox PA, 1990, "Ethnopharmacology and the search for new drugs Bioactive Compounds from Plants Ciba Foundation Symposium 154", Chichester, John Wiley & Sons, 153.
13. Cox P, Balick M., 1994, "The ethnobotanical approach to drug discovery". *Sci American*, 1994, Page no. page no.153.
14. Tiwari S, Singh A.2004, "Toxic and sub-lethal effects of oleadriin on biochemical parameters of freshwater air breathing murrel, *Chant punctatus* (Bloch)". *Indian J Exp Biolo*, 42: 153-154.
15. Tiwari S., 1998, "Plants: A Rich Source of Herbal Medicine. *Journal of Natural Products*", Vol 1, 154.
16. Ved DK, Mudappa A, Shankar D., 1998, "Regulating export of endangered medicinal plant species-need for scientific vigour". *Curr Sci*, 75: 154.
17. S. Kumar, BS. Bajwa, Singh Kuldeep and AN. Kalia, 2013 "AntiInflammatory Activity of Herbal Plants: A Review" *IJAPBC – Vol. 2(2)*, Apr-Jun.
18. Singh J, Singh AK, Pravesh R., 2003, "Product ion and trade potential of some important medicinal plants: an overview. In: Proceeding of first national interactive meet on medicinal and aromatic plants", CIMAP, Lucknow, India, 154.
19. Nadkarni, A.K., 2016, "Indian Materia Medica Asian" *Journal of Science and Technology* Vol. 07, 2000 Issue, 05, pp.2980-2983, May.
20. Cardinali PD and Esquifino IA., 2003, "Circadian disorganization in experimental arthritis. *Neuro Signals*"; 12: 267-282.
21. Pervical M., 1999, "Understanding the natural management of pain and inflammation", *Clinical Nutrition insights*: 4: 1-5.
22. S. Kumar, BS. Bajwa, Singh Kuldeep and AN. Kalia, 2013, "AntiInflammatory Activity of Herbal Plants: A Review" *IJAPBC – Vol. 2(2)*, Apr-Jun.
23. Serhan CN, Yacoubian S, Yang R., 2008, "Anti-inflammatory and proresolving lipid mediators". *Annu Rev Pathol*. 279-312.
24. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN., 2001, "Lipid mediator class switching during acute inflammation: signals in resolution". *Nat Immunol*. Jul;2 (7): 612 .
25. Serhan CN, Chiang N, Van Dyke TE., 2008, "Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators", *Nat Rev Immunol*. May; 8 (5): 349-361.
26. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. 1999, "Inducible cyclooxygenase antiinflammatory properties". *Nat Med*. Jun;5(6): 698-701.

27. Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, Fitzgerald D, Yaqoob MM, Gilroy DW. 2007, "Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2". Proc Natl Acad Sci U S A. 2007 Dec 26; (52):20979-84. Epub Dec 5: 104.
28. Dai C, Stafford RS, Alexander GC., 2005, "National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation". Arch Intern Med; 165: 171-177.
29. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA, "Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey". JAMA 2002; 287: Page no.337-344.
30. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al., 2005, "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial". N Engl J Med; 352:1092-102.
31. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M., 2004, "Risk of cardiovascular events and rofecoxib: cumulative meta-analysis". Lancet; 364.
32. Mc Gettigan P, Henry D., 2006, "Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2". JAMA; 44.
33. Avorn J., 2007, "Keeping science on top in drug evaluation". N Engl J Med 2007; 357: 633.
34. Cashman JN., 1996, "The mechanisms of action of NSAIDs in analgesia" PMID; 52 Suppl 5: 13-23
35. <http://www.nature.com/ni/journal/v6/n12/pdf/ni1275.pdf>
36. <http://www.pubmedcentral.gov/picrender.fcgi?artid=270694&blobtype=pdf>
37. http://www.imulan.com/Resources/ImSAIDS_Tech_Summary.pdf
38. Mathison RD, Befus AD, Davison JS, Woodman RC., 2003 "Modulation of neutrophil function by the tripeptide feG. BMC Immunol", Mar 4; 4:3. Epub, Mar 4.
39. Mathison RD, Davison JS., 2006, "The Tripeptide feG Regulates the Production of Intracellular Reactive Oxygen Species by Neutrophils". J Inflamm (Lond). Jun 15; 3(1): 9.
40. Mathison R, Lo P, Tan D, Scott B, Davison JS., 2001, "The tripeptide feG reduces endotoxin-provoked perturbation of intestinal motility and inflammation". Neurogastroenterol Motil. Dec; 13 (6): 599-603.
41. Dery RE, Mathison R, Davison J, Befus AD., 2001, "Inhibition of allergic inflammation by C-terminal peptides of the prohormone submandibular rat 1 (SMR-1)". Int Arch Allergy Immunol. an- Mar; 124(1-3): 201-204.
42. Dorota Kregiel, Ewelina Pawlikowska and Hubert Antolak. *Urtica* spp.: Ordinary Plants with Extraordinary Properties. *Molecules* 2018; 23: 1-21.
43. Hosam M. El-Seadawy, Kamilia A. Abo El-Seoud, Amal M. Kabbash, Mona El-Aasr and Ghada I. Attia. Phytochemical and biological investigation of *Urtica urens* L. growing in Egypt. *International research journal of pharmacy*. 2018; 9(1):25-35.
44. Massara Mzid, Sameh Ben Khedir, Maryem Ben Salem, Wafa Regaieg & Tarek Rebai. Antioxidant and antimicrobial activities of ethanol and aqueous extracts from *Urtica urens*. *Journal Pharmaceutical Biology*. 2017; 55(1):22-29.
45. Huda A. Al Doghaither, Ulfat M. Omar, Sawsan A. Rahimuddin and Ayat B. Al-Ghafari, Cytotoxic Effects of Aqueous Extracts of *Urtica urens* on Most Common Cancer Types in Saudi Arabia. *Journal of Biological Sciences*. 2016; 16: 242-246.
46. Zouhra Doukkali, Khalid Taghzouti, EL Houcine Boudida, Mohamed Nadjmouddine, Yahya Cherrah, and Katim Alaoui. Evaluation of anxiolytic activity of methanolic extract of *Urtica urens* in a mice model. *Behav Brain Funct*. 2015; 11: 19.
47. Nidal Amin Jaradat. Standardization the Crude Extracts of all *Urtica* plant Species Growing in Palestine for Quality Control of Cosmeceutical and Pharmaceutical Formulations. *International Journal of Pharmaceutical and Clinical Research*. 2015; 7(5): 368-373.
48. Ghada A. Taqa, Eman A. Mustafa, Siba M. Al-Haliem. Evaluation of AntiBacterial and Efficacy of plant extract (*Urtica urens*) on Skin Wound Healing in Rabbit. *International Journal of Enhanced Research in Science Technology & Engineering*. 2014; 3(1):64-70.
49. Carla Marrassini, Cristina Acevedo, Jorge Mino, Graciela Ferraro, Susana Gorzalczany. Evaluation of antinociceptive, anti-inflammatory activities and phytochemical analysis of aerial parts of *Urtica urens* L. 2010; 24(12):1807-1812.
50. Oukacha Amri, Abderrahmane Zekhnini, Abdellah Bouhaimi, Saida Tahrouch, Abdelhakim Hatimi. Anti-inflammatory Activity of Methanolic Extract from *Pistacia atlantica* Desf. Leaves. *Pharmacogn J*. 2018; 10(1): 71-76.
51. Sathiyabalan G, Michael Evanjaline R, Muthukumarasamy S, Mohan V.R. Anti-inflammatory Activity of Whole Plant of *Petiveria alliacea* L. (Phytolaccaceae). *Int. J. Pharm. Sci. Rev. Res.*, 2017; 47(2):123-125.

52. Kamau JK, Nthiga PM, Mwonjoria JK, Ngeranwa JJN, Ngugi MP. AntiInflammatory Activity of Methanolic Leaf Extract of *Kigelia Africana* (Lam.) Benth and Stem Bark Extract of *Acacia Hockii* De Wild in Mice. *Journal of Developing Drugs*. 2016; 5(2):1-8.
53. Abdullatif Azab, Ahmad Nassar and Abed N. Azab. Anti-Inflammatory Activity of Natural Products. *Molecules* 2016; 21(1321):1-19.
54. Rafik U. Shaikh, Mahesh M. Pund, Rajesh N. Gacche. Evaluation of antiinflammatory activity of selected medicinal plants used in Indian traditional medication system in vitro as well as in vivo. *Journal of Traditional and Complementary Medicine*. 2016; 6:355-361.
55. Jing Zhen, Yue Guo, Tom Villani, Steve Carr, Thomas Brendler, Davis R. Mumbengegwi, Ah-Ng Tony Kong, James E. Simon and Qingli Wu. Phytochemical Analysis and Anti-Inflammatory Activity of the Extracts of the African Medicinal Plant *Ximenia caffra*. *Journal of Analytical Methods in Chemistry*. 2015:1-9.
56. Md. Ali Asif Noor, Md. Zamiul Islam, Md. Sarwar Hosain, Md. Shahid Sarwar, Md. Mosiqur Rahman, Mamunur Rashid, Mohammad Safiqul Islam, Md. Asaduzzaman. Analgesic and anti-inflammatory activity of methanol extract of *Xanthosoma sagittifolium*. *Journal of Pharmacognosy and Phytochemistry* 2015; 4(3): 181-185.
57. Avijit Chatterjee, Biswarup Sen, Sumanta Das, Tapan Kumar Chatterjee. Anti-inflammatory and Analgesic Activity of Methanolic Extract of Medicinal Plant *Rhodiola rosea* L. Rhizomes. *International Journal of Pharma Research & Review*. 2015; 4(2):1-8.
58. Vashishtha Vishal, Sharma Ganesh N., Gaur Mukesh, Bairwa Ranjan. A review on some plants having anti-inflammatory activity. *The Journal of Phytopharmacology* 2014; 3(3): 214-221.
59. Oseni L.A. Amiteye D., Antwi S., Tandoh M., Aryitey G.M. Preliminary in vivo evaluation of anti-inflammatory activities of aqueous and ethanolic whole plant extracts of *Phyllanthus fraternus* on Carrageenan-induced Paw Oedema in Sprague-Dawley Rats. *Journal of Applied Pharmaceutical Science*. 2013; 3 (03): 062-065.
60. Mohini A. Phanse, Manohar J. Patil, Konde Abbulu. Pravin D. Chaudhari and Bhoomi Pate. In-vivo and in-vitro screening of medicinal plants for their anti-inflammatory activity: an overview. *Journal of Applied Pharmaceutical Science*. 2012; 02 (06): 19-33.
61. V Afsar, Y Mohan Reddy and K V Saritha. In vitro antioxidant activity and anti inflammatory activity of methanolic leaf extract of *boswellia serrata*. *Int. J. LifeSc. Bt & Pharm. Res.* 2012; 1(4):15-23.
62. Mohammad Shahadat Hossain, Mohammad Ehsanul Hoque Chowdhury, Sumana Das and Imtiaz Uddin Chowdhury. In-Vitro Thrombolytic and Anti-inflammatory Activity of *Swertia chirata* Ethanolic Extract. *Journal of Pharmacognosy and Phytochemistry*. 2012; 1(4):99-104.
63. Govindappa M., Naga Sravya S., Poojashri M. N., Sadananda T. S. and Chandrappa C. P. Antimicrobial, antioxidant and in vitro antiinflammatory activity of ethanol extract and active phytochemical screening of *Wedelia trilobata* (L.) Hitchc. *Journal of Pharmacognosy and Phytotherapy*. 2011; 3(3):43-51.
64. Seema Chaitanya Chippada, Sharan Suresh Volluri, Srinivasa Rao Bammidi and Meena Vangalapati. In Vitro Anti Inflammatory Activity Of Methanolic Extract Of *Centella Asiatica* By Hrbc Membrane Stabilisation. *Rasayan J.Chem.* 2011; 4(2): 457-460.
65. G. Leelaprakash, S.Mohan Dass. In vitro Anti-Inflammatory Activity of Methanol Extract of *Enicostemma Axillare*. *Int. J. Drug Dev. & Res.* 2011; 3 (3): 189-196.
66. Gambhire MN, Wankhede SS, Juvekar AR. Antiinfl ammatory Activity of Aqueous Extract of *Barleria cristata* Leaves. *J Young Pharm.* 2009; 1(3):220-224.
67. T. Dimo, Agathe L. Fotio, T.B. Nguiefack, E.A. Asongalem, P. Kamtchouing. Anti-inflammatory activity of leaf extracts of *Kalanchoe crenata* *Kalanchoe crenata* Andr. *Indian J Pharmacol.* 2006; 38(2):115-9.
68. Boulos L. *Flora of Egypt*. 1st ed. Cairo, Egypt: Al Hadara publishing; 1999. p. 373.
69. Parish S. The immigrant plants of southern California. *Bull South Calif Acad Sci.* 1920; 19:3-30.
70. Shaloot KH, Sharaf El-din A and Ahmed DA. *Plant life in the Nile delta*. Egypt; 2010.
71. Kavtaradze NS. Phenolic compounds from *Urtica urens* growing in Georgia. *Chem Nat Compd.* 2003; 39(3):314.
72. Patten G. Medicinal plant review *Urtica*. *Aust J Med Herbal.* 1993; 5:5-13.
73. Marrassini C, Acevedo C, Miño J, Ferraro G, Gorzalczy S. Evaluation of Antinociceptive, Antiinflammatory Activities and Phytochemical Analysis of Aerial Parts of *Urtica urens* L. *Phyther Res.* 2010; 24:1807-12.

74. Jimoh F, Adedapo A, Aliero A, Afolayan A. Polyphenolic and biological activities of leaves extracts of *Argemone subfusiformis* (Papaveraceae) and *Urtica urens* (Urticaceae). *Int J Trop Biol Conserv.* 2010; 58:1517–31.
75. Mukherjee PK. *Quality Control of Herbal Drugs*, 2nd Edition, Business Horizons, 2007; 2-14.
76. Kokate CK. Ed. *Practical Pharmacognosy*, 4th Edn., Vallabh Prakashan: 1994; 112:120.
77. Roopashree TS, Dang R, Rani SRH, Narendra C. Antibacterial activity of anti-psoriatic herbs: *Cassia tora*, *Momordica charantia* and *Calendula officinalis*. *International Journal of Applied Research in Natural Products* 2008; 1(3): 20-28.
78. Obasi NL, Egbuonu ACC, Ukoha PO, Ejikeme PM. Comparative phytochemical and antimicrobial screening of some solvent extracts of *Samanea saman* pods. *African journal of pure and applied chemistry* 2010; 4(9): 206-212.
79. Audu SA, Mohammed I, Kaita HA. Phytochemical screening of the leaves of *Lophira lanceolata* (Ochanaceae). *Life Science Journal* 2007; 4(4): 7579.
80. Olufunmiso, Olajuyigbe, O. and Afolayan, Anthony, J. (2011). phenolic Content and antioxidant property of the bark extract of *Ziziphus mucronata* wild. Subsp. *Mucronata* wild, *BMC, Complementary and alternative medicine.* 11: 130.
81. OECD, *Guideline for Testing of Chemicals-Acute Oral Toxicity-Acute Toxic Class Method.* Paris: OECD; 2001.
82. Singh M, Kumar V, Singh I, Gauttam V, Kalia AN. Anti-inflammatory activity of aqueous extract of *Mirabilis jalapa* Linn. leaves. *Pharmacognosy research.* 2010; 2(6):364.
83. Animal models for evaluation of arthritis drugs. Greenwald RA. *Methods Find Exp Clin Pharmacol.* 1991; 13(2):75-83.

